20 Young Companies in the Money
More than a month after biopharma stocks began to tank, investors and market-watchers remain divided on whether the Wall Street swoon is just the proverbial bump in the road, or a pothole that will stymie startups for months, if not years, to come.
An answer is unlikely to emerge from this year’s GEN tally of early-stage drug and diagnostic developers that closed on millions of dollars in private funding during 2015 (as of deadline Read more [...]